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Studies have suggested that enzootic strains of Ven-
ezuelan equine encephalitis (VEE) subtype ID in the Ama-
zon region, Peru, may be less pathogenic to humans than 
are epizootic variants. Deaths of 2 persons with evidence of 
acute VEE virus infection indicate that fatal VEEV infection 
in Peru is likely. Cases may remain underreported.
V
enezuelan equine encephalitis (VEE) is an emerging 
zoonotic disease in the Amazon region of Peru. Af-
ter dengue, it is considered the second most important ar-
boviral disease in Peru. Most human infections with VEE 
virus (VEEV) are caused by subtype ID (1–5), and within 
subtype ID, 6 genotypes have been described (6). In Peru, 
the Colombia/Venezuela, Panama/Peru, and Peru/Bolivia 
genotypes have been identiﬁ  ed among VEEV subtype ID 
isolates (1,5,7). Epidemiologic investigations have failed 
to detect neurologic disease or deaths among >200 VEE 
cases in this country (T.J. Kochel, unpub. data). Only 2 fa-
tal cases with VEEV subtype ID have been reported, both 
in Panama (6,8). In contrast, fatal cases with neurologic 
complications (estimated mortality rate 0.7%) have been 
described regularly for human outbreaks caused by VEEV 
subtypes IAB and IC (9–12). On the basis of these reports, 
it has been suggested that enzootic VEEV strains in Peru 
may be less pathogenic to humans than the epizootic vari-
ants (13). However, only 200 cases identiﬁ  ed in Peru may 
not be enough to make such an assertion.
We recently described a severe infection in a 3-year-
old boy who had VEEV subtype ID (14). Here we describe 
2 fatal infections in persons with evidence of acute VEEV 
infection in Peru. One patient had conﬁ  rmed subtype ID.
The Study
In 2000, the Naval Medical Research Center Detach-
ment (NMRCD) and the Ministry of Health of Peru estab-
lished a passive surveillance study to determine arboviral 
causes of febrile illness (protocol NMRCD.2000.0006). 
Patients with acute, undifferentiated febrile illness of <7 
days were invited to enroll, and demographic and clinical 
information was obtained at the time of enrollment. Blood 
samples were obtained and assayed by virus isolation, and 
convalescent-phase samples were obtained 10 days to 4 
weeks later for serologic studies.
Patient 1 was a 7-year-old girl from San Benito, a rural 
community near Yurimaguas city (Figure 1), who on June 
19, 2006, was noted to have nasal congestion, sneezing, 
chills, malaise, myalgia, abdominal pain, and fever fol-
lowed by several episodes of watery, nonbloody feces, and 
vomiting. Her condition rapidly worsened, and she began 
having tonic–clonic seizures. The next day the involuntary 
movement and vomiting stopped; however, other signs 
worsened and she became somnolent and prostrate. Later 
that day she was admitted to the Hospital Santa Gema of 
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Figure 1. Selected sites in Peru of passive surveillance study to 
determine arboviral causes of febrile illness in Peru, established 
in 2000 by Naval Medical Research Center Detachment and the 
Ministry of Health of Peru (protocol NMRCD.2000.0006). Sites 
shown include those of 2 patients with evidence of acute Venezuelan 
equine encephalitis virus infection. Shaded area is Titicaca Lake.Yurimaguas with fever, dehydration, stupor, and signs of 
respiratory distress along with tonic–clonic seizures. Tem-
perature was 40°C (104°F), blood pressure 90/50 mm Hg, 
respiratory rate markedly increased, and heart rate 132 
beats/min. Distal cyanosis, nasal ﬂ  aring, rhonchi without 
crackles, and supraclavicular and intercostal retractions 
were noted, but no jaundice, lymphadenopathy or conjunc-
tival hemorrhage were observed. Hepatomegaly (liver 4 cm 
under the costal border), stupor, and neck stiffness were 
also noted. Laboratory test results showed a left shift in the 
leukocyte count and renal failure (Table 1). Blood smears 
were negative for malaria parasites. Preliminary diagnoses 
were sepsis, convulsive status, and respiratory distress. 
Later that day the patient was considered to have a compli-
cated, febrile, neurologic illness, and a blood sample was 
sent for advanced analysis at the NMRCD in Lima, Peru, 
and the National Institute of Health of Peru.
The girl was given supportive therapy with broad spec-
trum antibiotics, intravenous hydration, oxygen, and anti-
convulsive medications (diazepam, phenytoin). On June 
21, seizures persisted, and the patient became comatose 
and later died of respiratory arrest. Arterial blood gasses 
and electrolytes could not be measured because of the lim-
ited capacity of the hospital laboratory. The girl’s parents 
did not consent to lumbar puncture or autopsy.
Examination of the girl’s serum in Vero cells identiﬁ  ed 
VEEV, and sequencing and phylogenetic analyses using 
previously described methods further identiﬁ  ed it as sub-
type ID Panama/Peru genotype (Figure 2) (15). On the day 
the serum was collected (1 day after onset of signs), vire-
mia titer was 1.8 ×104 PFU/mL, similar to titers from other 
VEEV-infected study patients who did not have neurologic 
complications (Table 2). The National Institute of Health 
reported the sample to be negative for leptospiral and rick-
ettsial organisms, according to ELISA immunoglobulin 
(Ig) M and indirect immunoﬂ  uorescent assays, respective-
ly. Blood and cerebrospinal ﬂ  uid cultures for bacteria were 
not attempted.
Patient 2 was a 25-year-old man from Puerto Maldona-
do, a city in the department of Madre de Dios (Figure 1). 
On February 24, 2005, he reported fever, headache, myal-
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Table 1. Laboratory test results for 2 patients infected with Venezuelan equine encephalitis virus, Peru* 
Testing Patient no. 1  Patient no. 2  Reference range 
Date blood collected  2006 Jun 20  2005 Feb 28  2005 Mar 1 
Hematocrit, %  36 36 22 38–44
Thromocytes, cells/mm
3 233,000 143,750 NM 150,000–450,000 
Leukocytes 
 Total,  cells/mm
3 21,450 3,900 NM 4,500–10,000 
 Bands,  %  7 4 NM 3–5
  Segmented cells, %  84 72 NM 55–65
 Eosinophils,  %  0 0 NM 0.5–4.0
 Monocytes,  %  0 14 NM 3–8
 Lymphocytes,  %  9 10 NM 25–35
ESR, mm/h  41 NM NM 1–15
Creatinine, mg/dL  2.1 9.1 8.8 0.8–1.4
Urea, mg/dL  115 206 238 20–45
*NM, not measured; ESR, erythrocyte sedimentation rate. 
DEI5191 PE94 AF004852
FSL507 PE01 AY966915
71D1392 PE71 U88648
71D1394 PE71 U88649
75D143 PE75 U88650
IC 3908 VE95 U55350
FSL3344 PE07 GQ844875
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FSL2649 PE06 GQ336477
FSL2314 PE06 EU935737
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FSL201 PE00GQ503335
FSL240 PE00 GQ503336
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FSL1065 PE03 GQ336473
FSL1063 PE03 GQ161198
FSL995 PE03 GQ336472
IQT6088 PE98 AY966908
PE30609 PE98 AY966915
FSL252 PE00 GQ503337
IQT7988 PE98 AY966911
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Figure 2. Neighbor-joining phylogenetic tree of Venezuelan equine 
encephalitis virus (VEEV) complex based on partial sequence of 
the PE2 segment (nucleotide positions ≈8385–9190 of the VEEV 
genome). The tree was rooted by using an outgroup of 3 major 
lineages of Eastern equine encephalitis virus (EEEV). The strain 
isolated from a 7-year-old girl who died from acute VEEV infection 
in Peru, June 21, 2006, is in boldface. Viruses are labeled by 
code designation, abbreviated location name, year of isolation 
(last 2 digits of year only), and GenBank accession numbers of 
the corresponding sequences. PA, Panama; GU, Guatemala; 
MX, Mexico; FG, French Guiana; VE, Venezuela; BR, Brazil; AG, 
Argentina; PE, Peru; FL, Florida. Numbers indicate bootstrap 
values. Scale bar indicates nucleotide substitutions per site.VEE and Human Deaths
gia, nausea, vomiting, and diarrhea. Because he was from 
an outlying rural area, he was taken to the local health cen-
ter where he received intravenous rehydration and partially 
recovered. The patient stayed at home, but his signs and 
symptoms persisted. On February 27, jaundice and epistax-
is developed, and the local health center referred him to 
the Santa Rosa Hospital in Puerto Maldonado, where he 
was admitted on February 28. The patient’s status deterio-
rated quickly; hematuria and hematemesis were followed 
by liver and renal failure (Table 1), and the patient died on 
March 1. Postmortem examination found multiple hemor-
rhages in his lungs, kidneys, and stomach. A serum sample 
collected at the time of admission was positive for VEEV 
antibodies, according to ELISA IgM (titer 6,400) (2,3). The 
case was presumed to be VEE, although virus isolation at-
tempts were unsuccessful. Serologic assays produced nega-
tive results for leptospiral and arboviral diseases, including 
dengue, Mayaro, yellow fever, Oropouche, and Eastern 
equine encephalitis.
Conclusions
Patient 1 had no previous history of neurologic disease 
or poor health. VEEV subtype ID infection (Panama/Peru 
genotype) was conﬁ  rmed. Because her viremia titer was 
similar to titers of other patients who did not have neuro-
logic complications and survived VEEV infection, viremia 
levels alone may not account for the difference in disease 
outcome. Although VEEV was isolated from the patient’s 
serum and she met the Centers for Disease Control and Pre-
vention’s diagnostic criteria for conﬁ  rmed VEE (www.cdc.
gov/ncphi/disss/nndss/casedef/arboviral_current.htm), we 
cannot rule out concomitant bacterial meningitis in this pa-
tient, who had meningismus and leukocytosis. The limited 
extent of our diagnostic procedures prevent us from con-
cluding with certainty that VEEV infection was the main 
cause of death.
Patient 2 had severe hemorrhagic complications. 
Although an uncommon manifestation of VEEV infec-
tion, these complications have been reported elsewhere 
(6,8,14). To date, only VEEV subtype ID has been isolat-
ed in and around Puerto Maldonado (5); thus, this patient 
was probably also infected with this subtype. However, 
we cannot unequivocally state that the patient died from 
VEEV infection.
Both fatal cases described in this report were clinically 
similar to previously reported enzootic and epidemic VEE 
cases (1,6,8,9,11,14). Initially, both patients had fever, body 
aches, vomiting, and diarrhea (Table 1) (1, 6,8,9,11), which 
are also caused by other tropical diseases like dengue. Only 
some patients, such as patient 1 from Yurimaguas, had neu-
rologic complications (Table 1), which are more commonly 
observed in children<15 years of age (6,8,9,11).
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Table 2. Venezuelan equine encephalitis virus titers in 10 patients, Peru 
Signs and symptoms 
Patient
code
Age,
y/sex  Location
Date of 
symptom 
onset
Date of 
blood
collection
Serum
titer,
PFU/mL Death Bleed* Fever Seizure GI† Resp‡ Aches§
Patient 1 
FSL2612
7/F Yurimaguas, 
Loreto
2006
Jun 19 
2006
Jun 20 
1.8 × 10
4 +–++ + + +
FSL2649 32/M Yurimaguas, 
Loreto
2006
Aug 7 
2006
Aug 8 
3.4 × 10
4 ––+– + + +
IQE1149 14/F Iquitos, Loreto  2005
Apr 14 
2005
Apr 15 
1.0 × 10
3 ––+– – – +
IQE831 8/F Iquitos, Loreto  2005
Mar 13 
2005
Mar 14 
3.0 × 10
2 ––+– – – +
IQE3605 6/M Iquitos, Loreto  2006
Apr 3 
2006
Apr 4 
1.0 × 10
2 ––+– + – +
IQE3741 10/F Iquitos, Loreto  2006
Apr 21 
2006
Apr 24 
5.0 × 10
2 ––+– + – +
IQE5023 7/M Iquitos, Loreto  2007
Feb 27 
2007
Feb 28 
1.3 × 10
4 ––+– + – +
FMD1737 18/M Puerto
Maldonado,
Madre de Dios 
2007
Dec 17 
2007
Dec 19 
5.0 × 10
2 ––+– – – +
FMD1905 21/F Puerto
Maldonado,
Madre de Dios 
2008
Feb 9 
2008
Feb  12 
3.0 × 10
3 ––+– + – +
Patient 2¶  25/M Puerto
Maldonado,
Madre de Dios 
2005
Feb 24 
2005
Feb 28 
NM + + + – + – +
*Epistaxis, bleeding gums, ecchymosis, purpura, hematochezia, or melena. 
†Gastrointestinal (nausea, vomiting, diarrhea, or abdominal pain). 
‡Respiratory (cough, dyspnea, or cyanosis). 
§Arthralgia, myalgia, bone pain, malaise, or prostration. 
¶Virus isolation attempts unsuccessful; ELISA immunoglobulin M results positive for Venezuelan equine encephalitis. NM, not measured. Our surveillance activities were limited to only 8 sur-
veillance sites in Peru (Figure 1), so VEE cases in other 
areas may remain undiagnosed. Because of the lack of sur-
veillance activities and proper diagnostic capabilities, fatal 
VEEV infection in Peru is likely; many cases may remain 
underreported in isolated rural locations where the disease 
is most common. Additional studies are needed to fully 
measure the extent and effects of VEE in Peru.
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